Skip to main content
Clinical Trials/JPRN-jRCTs031210314
JPRN-jRCTs031210314
Recruiting
N/A

Biomarker development study of pain quantification in patients with chronic pain using AMPA receptor density as an index

Miyazaki Tomoyuki0 sites60 target enrollmentSeptember 15, 2021

Overview

Phase
N/A
Intervention
Not specified
Conditions
Chronic pain
Sponsor
Miyazaki Tomoyuki
Enrollment
60
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
September 15, 2021
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Miyazaki Tomoyuki

Eligibility Criteria

Inclusion Criteria

  • Patients that meet all of the following criteria 1\) to 4\).
  • 1\) Patients having sustained pain that lasts for 3 months or longer
  • 2\) Patients who meet any of each following (1\) to (3\) without any overlap with each other
  • (1\) Patients having postoperative pain that was developed after surgery: Patients must meet the following (A) and (B)
  • (A) Pain that is observed around surgical sites and developed after surgery
  • (B) Pain that onset was within 3 months after surgery
  • (2\) Patients having pain caused by psychosocial factors: Patients must meet each criterion (A) or (B) and also meet the conditions of (C) and (D).
  • (A) Pain that followed Neurotic symptoms (psychiatric symptoms) such as anxiety and depressive symptoms
  • (B) Those corresponding to F45\.4 Persistent somatic symptom pain disorder in ICD\-10 or Physical symptom pain is the main symptom in DSM\-5
  • (C) Does not meet the following diagnostic criteria;

Exclusion Criteria

  • 1\) Implantation of metal substances and pacemakers
  • 2\) head, neck and body size not suitable for MRI scanner
  • 3\) A tattoo larger than one point (including tattoo and art makeup)
  • 4\) Advanced claustrophobic
  • 5\) A remarkable variant of brain structure (including congenital and traumatic)
  • 6\) Patient with renal dysfunction (Serum creatinine 1\.5 mg / dl or more)
  • 7\) Patient with liver dysfunction (AST 150 IU / L or more ALT 150 IU / L or more)
  • 8\) Combination of serious neurologic diseases (neurodegenerative diseases, cases of cerebral hemorrhage and cerebral infarction which are not slight in the image before this study participation)
  • 9\) Sensitive to alcohol
  • 10\) Participating in unapproved nuclear medicine clinical trials and clinical trials within 6 months prior to enrollment

Outcomes

Primary Outcomes

Not specified

Similar Trials